Benzinga | Sep 30, 2021 04:36PM EDT

Immunome To Present Preclinical Data On Anti IL-38 Antibody Program At The American Association For Cancer Research NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that it will be making an oral poster presentation on the company's anti IL-38 antibody program at the upcoming joint meeting of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 7-10, 2021.

Presentation Details:

Title: "IMM20324, a first-in-class, anti-interleukin-38 monoclonal antibody, rescues myeloid cell activation in vitro and induces robust anti-tumor responses in vivo."

Authors: John P. Dowling, et al.

Abstract Number: LBA022

Date/Time: All poster presentations are made available by the conference at the opening of the meeting on October 7, 2021, at 9:00am E.T.